Patients receiving dialysis living in communities with a high percentage of black residents are known to have worse morbidity and mortality outcomes, and a study presented Saturday at the American Society of Nephrology Kidney Week 2019 meeting found that patients receiving dialysis in those communities also had higher hospitalization rates.
Patients receiving dialysis living in communities with a high percentage of black residents are known to have worse morbidity and mortality outcomes, and a study presented Saturday at the American Society of Nephrology Kidney Week 2019 meeting found that patients receiving dialysis in those communities also had higher hospitalization rates.
Researchers analyzed data from the US cohort of the Dialysis Outcomes and Practice Patterns Study (US-DOPPS) to try to understand what causes the worse outcomes. The analysis included 4567 patients on hemodialysis from 154 facilities in 127 zip codes from the US-DOPPS phases 4-5 (2010-2015) linked to American Community Survey (ACS) data.
Dialysis facility zip code were divided into tertile of percent black residents. Patients receiving dialysis in facility zip codes located in communities with a higher (tertile 3: ≥14.4%) versus lower (tertile 1: ≤1.8%) percentage of black residents were more likely to be younger, black, live in urban areas, of a lower socioeconomic class, more likely to have a catheter as a vascular access, and have fewer comorbidities.
Patients receiving dialysis in communities with a high percentage of black residents had 32% higher hospitalization rates despite having equivalent dialysis care, according to Ladan Golestaneh, MD, MS. The association remained after adjusting for individual race, clinical comorbidities, community-level poverty, and dialysis quality and adherence.
While the tertile 3 facilities were more likely to be for-profit and had higher patient counts, they did not differ with respect to clinical quality benchmarks or dialysis adherence.
Golestaneh, of Albert Einstein College of Medicine/Montefiore Medical Center, said the difference “is likely not a result of differences in quality of dialysis care, adherence practices, or clinical factors, but rather a result of as yet unidentified community level determinants of health. Healthcare disparities continue to exist even after measures taken by Centers for Medicare and Medicaid services to bridge the quality gap, through measures such as the dialysis Quality Incentive Program, to promote high-quality services in outpatient dialysis facilities in communities across the US."
The other institutions involved in the study were the Arbor Research Collaborative for Health in Ann Arbor, Michigan, and Vanderbilt University Medical Center in Nashville, Tennessee.
The researchers recommended that future studies should examine the role of social support, access to care for pre—end-stage renal disease and specialty service care, as well as patient engagement strategies.
Reference
Golestaneh L, Cavanaugh KL, Karaboyas A, Melamed ML, Johns TS, Norris KC. Urban segregation and hospitalization outcomes in patients on hemodialysis. Presented at: American Society of Nephrology Kidney Week 2019, Washington, DC; November 5-10, 2019. Abstract OR060.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More